-
1
-
2تقرير
المساهمون: Elena Succurro, Associate Professor in Internal Medicine
المصدر: Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. F Dbetes Atlas: Global estates of dbetes prevalence for 2017 and projectns for 2045. Dbetes Res Cl Pract. 2018 Apr;138:271-281. do 10.1016/j.dbres.2018.02.023. Epub 2018 Feb 26.
Vaccaro O, Eberly LE, Neaton JD, Yang L, RcardG, Stamler J; Multle Rk Factor terventn Trl Research Group. pact of dbetes and prevus myocardl farctn on long-term surval: 25-year mortaly follow-up of prary screenees of the Multle Rk Factor terventn Trl. Arch tern Med. 2004 Jul 12;164(13):1438-43. do 10.1001/archte.164.13.1438.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortaly from coronary heart dease subjects wh type 2 dbetes and nondbet subjects wh and whout prr myocardl farctn. N Engl J Med. 1998 Jul 23;339(4):229-34. do 10.1056/NEJM199807233390404.
Kannel WB, McGee DL. Dbetes and cardvascular rk factors: the Framgham study. Cculatn. 1979 Jan;59(1):8-13. do 10.1161/01.c.59.1.8.
Dbetes Control and Complatns Trl Research Group; Nathan DM, Genuth S, Lach J, Cleary P, Crofford O, Dav M, Rand L, Sbert C. The effect of tense treatment of dbetes on the development and progressn of long-term complatns sul-dependent dbetes mellus. N Engl J Med. 1993 Sep 30;329(14):977-86. do 10.1056/NEJM199309303291401.
tense blood-glucose control wh sulphonylureas or sul compared wh conventnal treatment and rk of complatns patnts wh type 2 dbetes (UKPDS 33). UK Prospecte Dbetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum : Lancet 1999 Aug 14;354(9178):602.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Kogl J, Korn S, Lach JM, McGue DK, Penca MJ, Standl E, Ste PP, SuryawanshS, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of Saglt on Cardvascular Outcomes Type 2 Dbetes. N Engl J Med. 2015 Jul 16;373(3):232-42. do 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum : N Engl J Med. 2015 Aug 6;373(6):586.
Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Sca BM. Glucose-lowerg drugs or strategs and cardvascular outcomes patnts wh or at rk for type 2 dbetes: a meta-analys of randomed controlled trls. Lancet Dbetes Endocrol. 2015 May;3(5):356-66. do 10.1016/S2213-8587(15)00044-3. Epub 2015 Mar 17.
Standards of medal care dbetes--2015: summary of revns. Dbetes Care. 2015 Jan;38 Suppl:S4. do 10.2337/dc15-S003. No abstract avaable.
Abdul-GhanMA, Norton L, Defronzo RA. Role of sodm-glucose cotransporter 2 (SGLT 2) hors the treatment of type 2 dbetes. Endocr Rev. 2011 Aug;32(4):515-31. do 10.1210/er.2010-0029. Epub 2011 May 23.
FerrannE, MuscellE, Frascerra S, BaldS, MarA, Hee T, Broedl UC, Woerle HJ. Metabol response to sodm-glucose cotransporter 2 hn type 2 dbet patnts. J Cl vest. 2014 Feb;124(2):499-508. do 10.1172/JC2227. Epub 2014 Jan 27. Erratum : J Cl vest. 2014 Apr 1;124(4):1868.
Zman B, Wanner C, Lach JM, Fchett D, BluhmkE, Hantel S, Mattheus M, Devs T, Johansen OE, Woerle HJ, Broedl UC, zucchSE; EMPA-REG OUTCOME vestators. Empaglloz, Cardvascular Outcomes, and Mortaly Type 2 Dbetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. do 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Chton R, Tkanen Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Effects of empaglloz on blood pressure and markers of arterl stfness and vascular restance patnts wh type 2 dbetes. Dbetes Obes Metab. 2015 Dec;17(12):1180-93. do 10.1111/dom.12572. Epub 2015 Oct 9.
Tkanen Narko K, Zeller C, Green A, SalsalA, Broedl UC, Woerle HJ; EMPA-REG BP vestators. Empaglloz reduces blood pressure patnts wh type 2 dbetes and hypertensn. Dbetes Care. 2015 Mar;38(3):420-8. do 10.2337/dc14-1096. Epub 2014 Sep 30.
Rosenstock J, Jelaska A, Frapp G, SalsalA, K G, Woerle HJ, Broedl UC; EMPA-REG MDTrl vestators. proved glucose control wh weht loss, lower sul doses, and no creased hypoglycem wh empaglloz added to trated multle day jectns of sul obese adequately controlled type 2 dbetes. Dbetes Care. 2014 Jul;37(7):1815-23. do 10.2337/dc13-3055. Epub 2014 Jun 14.
Santos-Gallego CG, Requena-anez JA, San Anton R, hawa K, Watanabe S, Patoste B, Flores E, Garc-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badon JJ. Empaglloz Amelrates Adverse Left Ventrular Remodelg Nondbet Heart Faure by Enhancg Myocardl Energets. J Am Coll Cardl. 2019 Apr 23;73(15):1931-1944. do 10.1016/j.jacc.2019.01.056.
zzo P, Chareonthaawee P, Dutka D, Betterge DJ, FerrannE, CamPG. dependent assoctn of type 2 dbetes and coronary artery dease wh myocardl sul restance. Dbetes. 2002 Oct;51(10):3020-4. do 10.2337/dbetes.51.10.3020.
Nhawa J, Ohtake T, Yokoyama Watanabe T, Momose T, SasakY. Sple method to quanty myocardl glucose metabolm from MB rat myocardl FDG PET. Ann Nucl Med. 1996 Aug;10(3):323-8. do 10.1007/BF03164739.
Gerber BL, OrdoubadFF, Wns W, Vanoverschelde JL, KnuutMJ, Janr M, Melon P, Blanksma PK, Bol A, Bax JJ, Mel JA, CamPG. Posron emsn tomography usg(18)F-fluoro-deoxyglucose and euglycaem hypersulaem glucose clamp: optal crer for the predtn of recovery of post-chaem left ventrular dysfunctn. Results from the European Communy Concerted Actn Multenter study on use of(18)F-fluoro-deoxyglucose Posron Emsn Tomography for the Detectn of Myocardl Vby. Eur Heart J. 2001 Sep;22(18):1691-701. do 10.1053/euhj.2000.2585.
MarMA, Succurro E, FrontonS, MastronnS, ArturF, Sccqua A, Lauro R, Hral ML, Pertone F, SestG. sul sensy, beta-cell functn, and cret effect duals wh elevated 1-hour postload plasma glucose levels. Dbetes Care. 2012 Apr;35(4):868-72. do 10.2337/dc11-2181. Epub 2012 Feb 22.
MorbellS, MarC, AdamGF, KudomN, CamerG, zzo P, Massollo M, Capan S, Bodrato S, VerardMT, Papad F, Cordera R, KnuutJ, Scoparo N, SambucetG. Tsue specy fastg glucose utatn slhtly obese dbet patnts submted to bartr surgery. Obesy (Sver Sprg). 2013 Mar;21(3):E175-81. do 10.1002/oby.20003.
Cerquea MD, Wesman NJ, Dsn V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, VeranMS; Ameran Heart Assoctn Wrg Group on Myocardl Segmentatn and Regtratn for Cardc agg. Standarded myocardl segmentatn and nomenclature for tomograph agg of the heart. A statement for healthcare professnals from the Cardc agg Commtee of the Counc on Clal Cardlogy of the Ameran Heart Assoctn. Cculatn. 2002 Jan 29;105(4):539-42. do 10.1161/hc0402.102975. No abstract avaable.
Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetesالوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04183868Test
